Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Terns Pharmaceuticals Inc TERN

Healthcare Biotechnology
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors... see more

Recent & Breaking News (NDAQ:TERN)

Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology

GlobeNewswire March 27, 2023

Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences

GlobeNewswire March 2, 2023

Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference

GlobeNewswire February 2, 2023

Terns Pharmaceuticals to Present at B. Riley Securities' 3rd Annual Oncology Conference

GlobeNewswire January 12, 2023

Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2023

Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire December 23, 2022

Terns Announces Pricing of $75 Million Public Offering

GlobeNewswire December 20, 2022

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 20, 2022

Terns Announces Proposed Public Offering

GlobeNewswire December 19, 2022

Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit

GlobeNewswire December 1, 2022

Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire November 9, 2022

Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022

GlobeNewswire November 4, 2022

Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022

GlobeNewswire October 26, 2022

Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference

GlobeNewswire October 11, 2022

Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 7, 2022

Terns Announces $65 Million Oversubscribed Offering

GlobeNewswire August 12, 2022

Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire August 8, 2022

Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

GlobeNewswire July 27, 2022

Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress(TM) 2022

GlobeNewswire June 22, 2022

Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

GlobeNewswire June 8, 2022